HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After US FDA Objects To CBD Safety As NDIs, Supplement Industry Responds, What Else Is New?

Executive Summary

Rejection of two firms’ proposals for using hemp-derived CBD in supplement isn’t stirring US businesses selling CBD supplements to pull products from market. For one firm that filed an unsuccessful NDI notification for full-spectrum hemp extract CBD, FDA rejection was agenda item with numerous other business, regulatory and legislative developments in its latest quarter.

You may also be interested in...



NDI Notifications For CBD ‘Excluded’ On Arrival But US FDA Still Explains Where Safety Evidence Fails

CFSAN Office of Dietary Supplement Programs tells Charlotte’s Web and Irwin Naturals that not providing sufficient evidence of a reasonable assumption of safety for an NDI's intended use wasn’t the only reason each notification was rejected.

Mixing Food In Legislation Changing US FDA Cannabinoid Rules Could Choke Its Progress

Making lawful the use of hemp cannabinoids in supplements and food is a step in the right direction, but including food may doom it, say industry stakeholders. As well, CRN CEO Steve Mister notes FDA has stated reservations about using cannabinoids in food.

US House Co-signs Banking For Hemp Industry

House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.

Topics

UsernamePublicRestriction

Register

RS151658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel